John McAvoy, president and CEO of Consolidated Edison, discusses the state of the business with Mad Money host Jim Cramer.» Read More
Are stocks rallying on borrowed money? Alison Deans, Varick Asset Management, and Edward Ramos, Madison Square Investors, weigh in on what investors can expect in the second half of the year.
Jeff Kilburg, Kilburg Capital, and Neil Weinberg, American Banker, weigh in on the market ahead of the weekend.
Art Cashin, UBS, weighs in on whether the EU deal is enough to sustain a market rally.
Jeff Kilburg, Kilburg Capital, provides his play on Nike and Saks.
Art Cashin of UBS talks with Sue Herera about the sustainability of today's stock market rally and why he thinks the situation in Europe will be much clearer on Monday.
Jeff Kilburg, Kilburg Capital; Stephen Guilfoyle, Meridian Equity Partners; and Arthur Cashin, UBS Financial Services, discuss whether Friday's market surge will carry stocks into a second-half rally.
CNBC's Michelle Caruso-Cabrera offers a recap of the EU Summit as European markets close.
Jason Pride, Glenmede, and Charlie Smith, Fort Pitt Capital, discuss the market rally and whether it's real.
Robert Wetenhall, offers insight on housing and whether it could be showing signs of a real recovery.
Alan Knuckman, OneStopOption.com, shares his view of the markets.
Investors continue to debate which companies are set to benefit the most from the Supreme Court's health-care ruling, with Mike Weinstein, JPMorgan, and Josh Raskin, Barclays Capital.
A look at the U.S. markets ahead of the open, including the European Summit, oil's gains, and Research in Motion earnings, with CNBC's Kelly Evans.
Euro zone leaders agreed to radically restructure Spain’s 100 bilion euros ($125.9 billion) bank recapitalisation plan, allowing EU bailout funds to eventually be injected directly into teetering Spanish financial institutions, meaning Madrid can sweep the burden of the bailouts off its sovereign books.
Global investment banks are bracing themselves for a dismal second half, with further cuts in costs and staff, after a sharp drop in dealmaking and capital markets activity pushed down fees in the second quarter to their worst level in three year, the Financial Times reports.
Mad Money host Jim Cramer shares his final thoughts of the day.
Mad Money host Jim Cramer warns traders to be careful when investing in Ironwood Pharmaceuticals on the possibility the FDA turns down its drug candidate.
Mad Money host Jim Cramer explains why he thinks any improvement in Bed, Bath & Beyond's gross margin could send the stock right back up.
Last week, Celgene announced it was pulling its Revlimid application in Europe, and Mad Money host Jim Cramer explains why he thinks investors should buy into the stock now.
Mad Money host Jim Cramer rounds up today's trading session.
The Fast Money traders each share their trades for the third quarter.